(Bloomberg) -- Teva Pharmaceutical Industries Ltd.,
the world's biggest maker of generic drugs, and Sweden's Active
Biotech AB plan to push their experimental multiple sclerosis
pill to the last stage of clinical tests this year.
Tests on the medicine, called laquinimod, can proceed in
Europe and the United States now that discussions with the U.S.
Food and Drug Administration and its European counterpart have
concluded, the companies said in an e-mailed statement today. If
the tests succeed, laquinimod may reach the market by 2010,
Active Biotech Chief Executive Officer Sven Andreasson said.
Read more at Bloomberg Emerging Markets News
the world's biggest maker of generic drugs, and Sweden's Active
Biotech AB plan to push their experimental multiple sclerosis
pill to the last stage of clinical tests this year.
Tests on the medicine, called laquinimod, can proceed in
Europe and the United States now that discussions with the U.S.
Food and Drug Administration and its European counterpart have
concluded, the companies said in an e-mailed statement today. If
the tests succeed, laquinimod may reach the market by 2010,
Active Biotech Chief Executive Officer Sven Andreasson said.
Read more at Bloomberg Emerging Markets News
No comments:
Post a Comment